Lexicon Pharmaceuticals, Inc. (LXRX) Scheduled to Post Earnings on Wednesday
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.36) per share for the quarter.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $18.34 million. During the same period in the prior year, the firm posted ($0.37) EPS. Lexicon Pharmaceuticals’s revenue for the quarter was down 40.3% on a year-over-year basis. On average, analysts expect Lexicon Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) traded up $0.09 during mid-day trading on Friday, reaching $10.03. 181,029 shares of the company traded hands, compared to its average volume of 680,741.
TRADEMARK VIOLATION NOTICE: “Lexicon Pharmaceuticals, Inc. (LXRX) Scheduled to Post Earnings on Wednesday” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/11/03/lexicon-pharmaceuticals-inc-lxrx-scheduled-to-post-earnings-on-wednesday.html.
LXRX has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Wedbush reissued an “ourperform” rating and set a $39.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $21.00 target price on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $28.75.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.